November 28, 2017
AstraZeneca filed an application in Japan on November 27 seeking regulatory clearance for the front-line use of its EGFR tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) in patients with inoperable or recurrent EGFR mutation-positive non-small cell lung cancer (NSCLC). The submission...read more